Understanding the endocannabinoid system (ECS)

The endocannabinoid system is an endogenous signalling network that modulates nearly every organ system — pain, immunity, appetite, sleep, stress. It comprises at least two G-protein-coupled receptors (CB1, CB2), two main ligands (anandamide, 2-AG) and the degrading enzymes FAAH and MAGL. This is why phytocannabinoids like THC and CBD have any effect at all.

The endocannabinoid system in one sentence — and then in more detail

The endocannabinoid system (ECS) is an endogenous regulatory system that does not perform a function itself, but rather fine-tunes other systems: it dampens excessive signals and stabilises processes such as pain perception, appetite, sleep, stress response, immune response, and mood. It can be thought of as a fine-tuning mechanism that intervenes wherever the body falls out of balance.

It consists of three building blocks. First, the receptors: CB1 is primarily located in the central nervous system and mediates psychoactive effects, while CB2 is predominantly found on immune cells and in peripheral tissues. Second, the endogenous neurotransmitters anandamide and 2-AG, which are not stored in advance but produced on demand. Third, the degrading enzymes FAAH and MAGL, which break down these neurotransmitters after a short time.

The unique feature: endocannabinoids act retrogradely — they travel backward across the synaptic cleft and regulate the sending cell. This is the mechanism by which the system curbs excessive activity instead of generating new activity.

  • CB1: Brain and Nervous System — Psychoactivity, Pain Modulation, Appetite
  • CB2: immune cells and peripheral tissue — regulation of inflammation, no psychoactivity
  • Anandamide: short-lived, degraded by FAAH, linked to the «runner's high»
  • 2-AG: most abundant endocannabinoid by quantity, degraded via MAGL

Why THC and CBD have such different effects

THC binds directly and strongly to the CB1 receptor and activates it — hence the psychoactive effect, but also side effects such as racing heart or anxiety at high doses. CBD, on the other hand, barely binds to CB1 and acts indirectly: among other things, by inhibiting the degradation of the body's own endocannabinoids and targeting other receptor systems, such as serotonin and TRPV1 receptors. This is why CBD is non-intoxicating and why it can cushion the effects of THC to some extent.

The frequently cited entourage effect describes the hypothesis that the interaction of cannabinoids and terpenes produces a different effect profile than isolated individual substances. Evidence for this exists, but is not as clear-cut as product marketing likes to suggest — what is robust, above all, is the observation that CBD alters the side-effect profile of THC.

This cluster is for knowledge transfer and does not constitute medical advice. Anyone wishing to treat a medical condition should discuss this with a doctor; medical cannabis has been prescribable in Switzerland since 1 August 2022 without an exceptional permit from the FOPH.

The path through this cluster

The subpages go through the building blocks individually: the two receptor types, the neurotransmitters anandamide and 2-AG, the degradation enzymes FAAH and MAGL, the entourage effect, and the controversial concept of endocannabinoid deficiency.

Those dealing with the topic for the first time should read the receptor pages first — they explain the terms on which all other pages are built.

Medical cannabis in Swiss practice

Since the amendment of the law in August 2022, access to therapies that act directly on the endocannabinoid system has become significantly easier in Switzerland. Since then, Swiss doctors have been permitted to prescribe medical cannabis directly, without the need to obtain a time-consuming exceptional permit from the Federal Office of Public Health (BAG). This liberalization enables a more targeted treatment of chronic complaints where the body's own regulatory system has become unbalanced. Guidance by medical professionals is essential here in order to tailor the dosage individually to the patient's receptor density.

In practice, however, reimbursement by health insurance companies remains a hurdle, as it usually has to be reviewed on a case-by-case basis. In addition, patients must exercise extreme caution in road traffic. Switzerland enforces a strict zero-tolerance policy with a legal THC limit of 1.5 micrograms per litre of blood. Even with a medically prescribed therapy that modulates the ECS, driving ability can be legally classified as impaired, which is why close consultation with the treating practice and precise documentation are essential.

  • Direct prescription by Swiss physicians without FOPH authorization since August 2022.
  • Case-by-case review for reimbursement by the mandatory health insurance.
  • A strict limit of 1.5 µg/L THC in the blood severely restricts participation in road traffic.
  • Individual dose titration under medical supervision to avoid receptor saturation.

Risks and safety aspects of ECS modulation

Targeted modulation of the endocannabinoid system carries specific risks, which become particularly relevant with uncontrolled consumption. Overstimulation of CB1 receptors in the brain by high-dose THC can trigger acute side effects such as anxiety, paranoia, or a racing heart. Since the system is closely linked to stress regulation, overwhelming the receptors often leads to the opposite of the desired effect. In the event of adverse reactions or suspected poisoning, the Swiss emergency number 145 from Tox Info Suisse provides rapid, professional assistance for those affected and their relatives around the clock.

Another risk lies in the long-term adaptation of the body to external cannabinoids. With a persistently high intake of THC, a so-called downregulation of CB1 receptors can occur, in which the body reduces the number of available binding sites. This leads to the development of tolerance, weakening the body's own regulation by anandamide and 2-AG. Responsible use therefore requires regular breaks or very precise dosing in order to maintain the natural sensitivity of the finely tuned signalling system in the long term and avoid imbalances.

  • Risk of acute anxiety and a racing heart during overstimulation of CB1 receptors.
  • Tolerance development and receptor downregulation with long-term, high-dose consumption.
  • Tox Info Suisse (emergency number 145) as the official Swiss contact point for overdoses and poisoning.
  • Increased risk of psychological interactions in individuals with a corresponding predisposition.

Influence of lifestyle and daily life on the endocannabinoid system

The endocannabinoid system can be positively influenced not only by plant-derived active substances, but also by daily behaviours and lifestyle. Scientific evidence suggests that regular endurance training boosts the production of the body's own endocannabinoid, anandamide. The well-known phenomenon of the runner's high, which was long attributed exclusively to endorphins, is now significantly linked to the activation of the ECS. Moderate, consistent physical activity in the aerobic range is often sufficient to measurably increase circulating messenger substances in the blood.

In addition to exercise, sleep quality and stress management also play a crucial role in the balance of the ECS. Chronic stress leads to a continuous release of cortisol, which in turn can reduce the density of CB1 receptors in the brain and accelerate the breakdown of anandamide. Relaxation techniques, adequate recovery phases, and a balanced diet rich in essential fatty acids support the body's own synthesis of these messenger substances. Since endocannabinoids are formed from fatty acids, a healthy diet provides the necessary building blocks for the entire signalling system.

  • Increase in the body's own anandamide production through moderate endurance sports.
  • Protection of receptor density through targeted stress management and reduction of cortisol.
  • Importance of essential fatty acids in the diet as building blocks for endocannabinoids.
  • Regulating influence of healthy sleep on the daily rhythm of the signalling system.

Common mistakes when activating the system

A common mistake when using cannabinoids for ECS modulation is the assumption that a higher dose automatically achieves a stronger effect. The endocannabinoid system often responds biphasically. This means that low and moderate doses can have a calming or regulating effect, while very high doses produce the exact opposite effect and block or overstimulate the system. Users often tend to increase the dose too quickly if there is no immediate effect, instead of giving the body time to adapt to the altered receptor activity.

Another misunderstanding concerns the distinction between the different methods of consumption. Absorption via the mucous membranes, the lungs, or the gastrointestinal tract leads to completely different active substance concentrations and time courses in the body. Anyone who ignores pharmacokinetics risks undesirable accumulation or insufficient stimulation of the target receptors. In addition, it is often overlooked that illegal products with a total THC content of over one per cent are illegal in Switzerland and may contain uncontrolled contaminants that place an additional burden on the sensitive receptors of the ECS.

  • Disregarding the biphasic effect, where high doses trigger opposite effects.
  • Increasing the dose too quickly without considering the body's necessary adaptation time.
  • Lack of understanding regarding the different absorption rates and duration of action depending on the method of consumption.
  • Use of unregulated products with an illegal THC content exceeding the Swiss limit of one percent.

FAQ

What does the endocannabinoid system do in the body?

It is a regulatory system that stabilizes other processes: pain perception, appetite, sleep, stress response, immune response, and mood. It operates on demand — endocannabinoids are only produced when a cell needs them, and are rapidly degraded afterwards.

What is the difference between CB1 and CB2?

CB1 is primarily located in the central nervous system and mediates the psychoactive effects of THC as well as effects on pain and appetite. CB2 is predominantly found on immune cells and in peripheral tissue and is involved in regulating inflammatory processes — activation of CB2 does not produce intoxicating effects.

Is there an endocannabinoid deficiency?

The hypothesis of clinical endocannabinoid deficiency has been formulated for conditions such as migraine, fibromyalgia, and irritable bowel syndrome. It is plausible and is being researched, but is not considered an established diagnosis — there is no established test for it and no standard therapy derived from it.

Does CBD act through the same receptors as THC?

No. THC activates CB1 directly, whereas CBD barely binds to it. CBD acts indirectly, including by inhibiting endocannabinoid degradation and through other receptor systems such as serotonin and TRPV1 receptors. This explains why CBD is non-intoxicating and has a completely different side-effect profile.

Can the endocannabinoid system be overloaded?

Yes, the endocannabinoid system can be overloaded by a continuous or extremely high intake of external cannabinoids. In particular, high consumption of THC leads to the CB1 receptors in the brain being permanently occupied. As a protective response, the body reduces the number of these receptors, a process known as downregulation. The consequence is the development of tolerance, whereby the body's own neurotransmitters, such as anandamide, can no longer function properly. To avoid such an overload, moderate dosages and conscious consumption breaks are advisable.

How quickly does the ECS react to plant-derived cannabinoids?

The reaction time of the endocannabinoid system depends primarily on the chosen method of consuming the cannabinoids. When inhaled, the active ingredients enter the bloodstream directly via the lungs and reach the receptors in the brain within a few seconds to minutes. With oral ingestion, for example through oils or capsules, the substances must first pass through the gastrointestinal tract and the liver. Here, the onset of action often takes one to two hours, but the effect lasts significantly longer and is more consistent.

What role do Swiss pilot trials play in research into the ECS?

The Swiss pilot trials under Article 8b of the Narcotics Act (BetmG) enable the scientifically monitored dispensing of cannabis containing THC under controlled conditions. These time-limited studies, which are being conducted in various Swiss cities, provide valuable data on consumption patterns and the health effects on participants. Thanks to the standardised quality of the products, researchers can better understand how regular consumption affects the endocannabinoid system and the general well-being of the population, without the risks of the black market.

What happens in the event of a deficiency of the body's own cannabinoids?

A deficiency of the body's own cannabinoids is suspected of promoting various chronic conditions such as migraines, fibromyalgia, or irritable bowel syndrome. This clinical endocannabinoid deficiency hypothesis suggests that the body does not produce enough anandamide or 2-AG to maintain pain and inflammation regulation. Medical science is intensively researching this connection; however, there are currently no standardised tests to directly detect such a deficiency in daily clinical practice. Therapeutic approaches are therefore mostly based on cautious, individualised symptom management.